Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Current and future antithrombotic therapies]

A Uzan1

  • 1Rhône Poulenc Rorer, Centre de Recherches de Vitry-Alfortville, Vitry-sur-Seine.

Annales Pharmaceutiques Francaises
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[The salt content of food: a public health problem].

Annales pharmaceutiques francaises·2009
Same author

Combination of enoxaparin and fibroblast growth factor-1 increases myocardial blood flow and capillary density after myocardial infarction in rabbits.

European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes·2005
Same author

[Pharmacology, an innovative factor in therapeutic research].

Annales pharmaceutiques francaises·2005
Same author

[Introduction. Epidemiology].

Annales pharmaceutiques francaises·2004
Same author

[Thrombosis and ischemia: experimental data].

Archives des maladies du coeur et des vaisseaux·2002
Same author

[Protective effect of appendectomy on the development of ulcerative colitis. A case-control study].

Gastroenterologie clinique et biologique·2001

Antithrombotic therapies, while effective, carry bleeding risks. Research focuses on developing safer anticoagulants and hemostatic agents, especially for dental surgery, to minimize hemorrhage complications.

Area of Science:

  • Pharmacology
  • Hematology

Context:

  • Antithrombotic therapies are crucial but associated with significant hemorrhage risks.
  • Existing treatments like vitamin K antagonists, heparin, and aspirin have limitations and bleeding potential.

Purpose:

  • To review current antithrombotic agents, their bleeding risks, and available antidotes.
  • To discuss emerging anticoagulants and antiplatelet drugs, highlighting the need for specific antidotes.
  • To explore future research directions in hemostatic agents for improved safety.

Summary:

  • Thrombolytic agents and anticoagulants (heparin, vitamin K antagonists) carry bleeding risks, though some have antidotes.
  • Low molecular weight heparins offer good efficacy and tolerance for venous thrombosis.
  • New anticoagulants (Factor Xa, thrombin inhibitors) and antiplatelet drugs (GPIIb/IIIa antagonists) are under development but lack specific antidotes.

Related Experiment Videos

  • Future research aims to develop novel molecules targeting procoagulant pathways and thrombin receptors.

    • Impact:

    • Improved understanding of antithrombotic drug properties and risks.
    • Potential for developing safer anticoagulants and antiplatelet agents with specific antidotes.
    • Significant reduction in hemorrhage risk, particularly in dental surgery, through advanced hemostatic agents.